Advertisement

Pharmacy World and Science

, Volume 28, Issue 4, pp 207–214 | Cite as

Pharmacoeconomic comparison of Helicobacter pylori eradication regimens

  • Mesut SancarEmail author
  • Fikret Vehbi Izzettin
  • Sule Apikoglu-Rabus
  • Fatih Besisik
  • Nurdan Tozun
  • Gul Dulger
Research Article

Abstract

Background

Helicobacter pylori is the most important etiologic agent for development of peptic ulcer, chronic gastritis and gastric carcinomas. It is now well established that H. pylori eradication treatment is more cost-effective than acid suppressing therapies alone for the treatment of peptic ulcer disease. However, the comparative cost-effectiveness of various H. pylori eradication regimens is still not clear.

Objective

This study was designed to make a pharmacoeconomic comparison of different H. pylori eradication regimens in patients with peptic ulcer disease or chronic gastritis, using real-world cost and effectiveness data.

Setting

Istanbul University Hospital and Marmara University Hospital.

Method

A total of 75 patients diagnosed as H. pylori (+) by endoscopy were randomized to receive one of the seven H. pylori treatment protocols. These protocols were as follows: (LAC) = ‘lansoprazole 30 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid’ for 7 days and (OCM) = ‘omeprazole 20 mg bid + clarithromycin 250 mg bid + metronidazole 500 mg bid’; (OAM) = ‘omeprazole 40 mg qd + amoxicillin 500 mg tid + metronidazole 500 mg tid’; (MARB) = ‘metronidazole 250 mg tid + amoxicillin 500 mg qid + ranitidine 300 mg hs + bismuth 300 mg qid’; (OAC) = omeprazole 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid’; (OCA) = omeprazole 40 mg bid + clarithromycin 500 mg bid + amoxicillin 1 g bid’; (OAB) = ‘omeprazole 20 mg bid + amoxicillin 500 mg tid + bismuth 300 mg qid’ each for 14 days. Only direct costs were included in the analysis. Effectiveness was measured in terms of “successful eradication”. The cost-effectiveness ratios of the regimens were calculated using these effectiveness and cost data. The perspective of the study was assumed as the Government’s perspective.

Main outcome measure

Cost-effectiveness ratios of eradication regimens.

Results

MARB and OCA regimens were found to be more cost-effective than the other treatment regimens. The eradication rates and cost-effectiveness ratios calculated for these protocols were 90% (€158.7) for MARB and 90% (€195.8) for OCA regimen.

Conclusion

This study confirms the importance of using local pharmacoeconomic data. Analyses such as this give decision-makers the tools to choose a better treatment option which is both highly effective yet and has a low cost.

Keywords

Cost-effectiveness Eradication regimens Gastritis Helicobacter pylori Peptic ulcer Pharmacoeconomics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

The authors would like to thank the pharmaceutical firms Abfar, Deva, Eczacibasi, I.E.Ulagay, Ilsan-Iltas and Toprak for supplying the drugs used for this project.

Conflicts of interest: none declared.

References

  1. 1.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311–5PubMedCrossRefGoogle Scholar
  2. 2.
    Veldhuyzen SO, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. Can Med Assoc J 1997;156:1565–72Google Scholar
  3. 3.
    Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996;91:246–57PubMedGoogle Scholar
  4. 4.
    Van Der Weyden MB, Armstrong RM, Gregory AT. The 2005 Nobel Prize in physiology or medicine. The Helicobacter story illustrates some of the human hallmarks of revolutionary research. Med J Aust 2005;183:612–4Google Scholar
  5. 5.
    McGowan CC, Cover TL, Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology 1996;110:926–38PubMedCrossRefGoogle Scholar
  6. 6.
    Go MF. What are the host factors that place an individual at risk for Helicobacter pylori associated disease? Gastroenterology 1997;113(Suppl.):S15–S20PubMedGoogle Scholar
  7. 7.
    Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori. MALT lymphoma study group. Lancet 1995;345:1591–4PubMedCrossRefGoogle Scholar
  8. 8.
    Fendrick AM. Outcomes research in Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11(Suppl. 1):95–101PubMedCrossRefGoogle Scholar
  9. 9.
    Fendrick AM. The role of economic evaluation in the diagnosis and treatment of Helicobacter pylori infection. Gastroenterol Clin N Am 2000;29:837–51CrossRefGoogle Scholar
  10. 10.
    Marshall BJ. Helicobacter pylori: the etiologic agent for peptic ulcer. JAMA 1995;274:1064–6PubMedCrossRefGoogle Scholar
  11. 11.
    Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(Suppl. 2):59–69PubMedGoogle Scholar
  12. 12.
    Ford AC, Qume M, Moayyedi P, Arents NL, Lassen AT, Logan RF, McColl KE, Myres P, Delaney BC. Helicobacter pylori “test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838–44PubMedCrossRefGoogle Scholar
  13. 13.
    Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833–55PubMedCrossRefGoogle Scholar
  14. 14.
    Tennvall GR, Norinder A, Ohlin B. Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. Pharmacoeconomics 1999;16:297–306PubMedCrossRefGoogle Scholar
  15. 15.
    Chen SY, Wang JY, Chen J, Zhang XD, Zhang SS. Assessment of decisions in the treatment of Helicobacter pylori related duodenal ulcer: a cost-effectiveness study. J Gastroenterol Hepatol 1999;14:977–83PubMedCrossRefGoogle Scholar
  16. 16.
    Vakil N. Are the geographical and regional differences in Helicobacter pylori eradication? Can J Gastroenterol 2003;17(Suppl. B):30B–32BPubMedGoogle Scholar
  17. 17.
    McLoughin RM, O’Morain CA, O’Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol 2005;19:421–7CrossRefGoogle Scholar
  18. 18.
    O’Brien B, Goeree R, Mohammed AH, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995;155:1958–64PubMedCrossRefGoogle Scholar
  19. 19.
    Duggan AE, Tolley K, Hawkey CJ, Logan RFA. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model. BMJ 1998;316:1648–54PubMedGoogle Scholar
  20. 20.
    Marko D, Calvet X, Ducons J, Gnardiola J, Tito L, Bory F. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis. Helicobacter 2005;10:22–32PubMedCrossRefGoogle Scholar
  21. 21.
    Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997;157:87–97PubMedCrossRefGoogle Scholar
  22. 22.
    Andersen LP, Colding H, Kristiansen JE. Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate. Int J Antimicrob Agents 2000;14:231–4PubMedCrossRefGoogle Scholar
  23. 23.
    Chiba N. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Can J Gastroenterol 2000;14:885–9PubMedGoogle Scholar
  24. 24.
    Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. NEJM 1995;333:984–91PubMedCrossRefGoogle Scholar
  25. 25.
    Kung NN, Sung JJ, Yuen NW, Li TH, Ng PW, Lai WM, et al. One week ranitidine bismuth citrate versus colloidal bismuth subcitrate based anti-helicobacter triple therapy. Am J Gastroenterol 1999;94:721–4PubMedCrossRefGoogle Scholar
  26. 26.
    Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278–82PubMedCrossRefGoogle Scholar
  27. 27.
    Kantarceken B, Yildirim B, Karincaoglu M, Aladag M, Hilmioglu F. Helicobacter pylori and antibiotic resistance. Turk J Gastroenterol 2000;11:25–9CrossRefGoogle Scholar
  28. 28.
    Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdorffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997;11:323–9PubMedCrossRefGoogle Scholar
  29. 29.
    Vcev A, Stimac D, Vceva A, Takac B, Pezerovic D, Ivandic A. High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers. Helicobacter 1999;4:54–7PubMedCrossRefGoogle Scholar
  30. 30.
    Calvet X, Gene E, Lopez T, Gisbert JP. What is the optimal length of proton pump inhibitor-based triple therapies for Helicobacter pylori? Aliment Pharmacol Ther 2001;15:1067–76PubMedCrossRefGoogle Scholar
  31. 31.
    Jönsson B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand J Gastroenterol 1996;31(Suppl. 215):90–5Google Scholar
  32. 32.
    Bytzer P, O’Morain C. Treatment of Helicobacter pylori. Helicobacter 2005;10:40–46PubMedCrossRefGoogle Scholar
  33. 33.
    Clifton S, Galt K. Treatment of Helicobacter pylori infection. Immanuel Medical Center Pharmacy Memo 1997Google Scholar
  34. 34.
    Eralp Y, Davutoglu C, Uzunismail H, Oktay E. Efficacy of combination therapy with omeprazole, amoxicillin and clarithromycin treatment of patients with Helicobacter pylori associated gastritis and duodenal ulcer disease. Turk J Gastroenterol 1999;10:27–31Google Scholar
  35. 35.
    Unge P. Review of H. pylori eradication regimens. Scand J Gastroenterol 1996;31(Suppl. 2):74–81Google Scholar
  36. 36.
    Cutler AF, Vakil N. Evolving therapy for Helicobacter pylori infection: efficacy and economic impact in the treatment of patients with duodenal ulcer disease. Am J Man Care 1997;3:1528–34Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Mesut Sancar
    • 1
    Email author
  • Fikret Vehbi Izzettin
    • 1
  • Sule Apikoglu-Rabus
    • 1
  • Fatih Besisik
    • 2
  • Nurdan Tozun
    • 3
  • Gul Dulger
    • 4
  1. 1.Clinical Pharmacy Department, Faculty of PharmacyMarmara UniversityIstanbulTurkey
  2. 2.Gastroenterology Department, Faculty of MedicineIstanbul UniversityIstanbulTurkey
  3. 3.Gastroenterology Department, Faculty of MedicineMarmara UniversityIstanbulTurkey
  4. 4.Pharmacology Department, Faculty of PharmacyMarmara UniversityIstanbulTurkey

Personalised recommendations